Tesofensine for weight loss: what the trials actually show
Quick answer
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, dopamine, norepinephrine) that showed meaningful weight loss in a 2008 Phase 2 RCT but has not received FDA approval and carries documented cardiovascular side effects including elevated heart rate. The creator promotes it as both a cognitive enhancer and a GLP-1 adjunct for weight loss, neither of which has published clinical trial support. Patients on GLP-1 medications should not combine tesofensine without prescriber supervision, as no safety or efficacy data exists for that stack in humans.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @andimay77 actually say?
After a late Super Bowl night, the creator credits a "little wonderful capsule" of what she calls "Tessa Fensine" with eliminating her brain fog, restoring mental clarity, and giving her a full day of energy. She also claims tesofensine "helps aid in increased weight loss" whether taken alone or alongside GLP-1 medications, and directs viewers to a telehealth website for more information.
Two distinct claims are being made here. First, that tesofensine functions as a reliable cognitive and energy booster. Second, that it amplifies weight loss when stacked with GLP-1 drugs like semaglutide or tirzepatide. Neither of those claims comes with a disclaimer, a prescription context, or any mention of side effects. That matters a lot for a compound that works on the central nervous system.
Does the science back this up?
Tesofensine does have real weight loss data behind it, but the cognitive and energy claims are almost entirely unsupported by published human evidence. Let's be precise about what we know.
On weight: a Phase 2 randomized controlled trial by Astrup et al. (2008, The Lancet) showed tesofensine at 0.5 mg daily produced roughly 10.6% body weight loss over 24 weeks, outperforming placebo significantly. That is a real signal. The drug inhibits reuptake of serotonin, dopamine, and norepinephrine, which suppresses appetite and increases energy expenditure.
On cognition and energy: the norepinephrine and dopamine reuptake inhibition could plausibly produce a stimulant-like effect, but no published clinical trial has established tesofensine as a brain fog treatment or a cognitive enhancer. The creator is extrapolating from its mechanism, not citing evidence. That is a meaningful distinction. The same mechanism also raises cardiovascular concerns, including elevated heart rate and blood pressure, documented in the Astrup trial.
On GLP-1 stacking: there is no published human RCT data on combining tesofensine with semaglutide or tirzepatide. The additive weight loss claim is speculative.
What did they get wrong (or right)?
Credit where it is due: tesofensine is not snake oil. The weight loss data from Astrup et al. is legitimate, and interest in it as an adjunct obesity therapy is real. NeuroSearch advanced it into Phase 3 consideration. The creator is not inventing a compound.
What she got wrong is more serious, though. Framing a triple monoamine reuptake inhibitor as a casual morning capsule for energy and mental clarity, with zero mention of cardiovascular risks, is irresponsible. The Astrup trial noted increased heart rate and dry mouth as frequent adverse effects. Tesofensine structurally resembles stimulant-class compounds. Presenting it the way you would present a cup of coffee is misleading.
The "take it in conjunction with your GLP-1 medications" line is the most problematic moment. Stacking a norepinephrine-dopamine-serotonin reuptake inhibitor on top of a GLP-1 agonist without clinical supervision, individualized dosing assessment, and cardiac monitoring is not something a social media video should be casually encouraging. No safety data exists for that combination in published literature.
What should you actually know?
Tesofensine is not FDA-approved for any indication as of 2025. In the United States, it is available through compounding pharmacies as an investigational or off-label compound, which means formulations, dosing, and purity are not standardized the way they are for approved drugs. That is not automatically disqualifying, but it means the consumer burden of due diligence is higher, not lower.
If you are interested in tesofensine after seeing content like this, the right next step is a conversation with a licensed prescriber who can review your cardiovascular history, your current medications including any GLP-1 drugs, and your individual risk profile. The weight loss mechanism is real. The cognitive enhancement pitch is not supported. And the casual "message us today" call to action at the end of a hype video is not a substitute for a clinical intake.
Anyone already on semaglutide or tirzepatide should not add tesofensine based on a TikTok. The combination is understudied and carries theoretical risks that have not been evaluated in a controlled setting.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tesofensine for weight loss: what the trials actually show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, dopamine, norepinephrine) that showed meaningful weight loss in a 2008 Phase 2 RCT but has not received FDA approval and carries documented cardiovascular side effects including elevated heart rate.
FormBlends verdict
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, dopamine, norepinephrine) that showed meaningful weight loss in a 2008 Phase 2 RCT but has not received FDA approval and carries documented cardiovascular side effects including elevated heart rate. The creator promotes it as both a cognitive enhancer and a GLP-1 adjunct for weight loss, neither of which has published clinical trial support. Patients on GLP-1 medications should not combine tesofensine without prescriber supervision, as no safety or efficacy data exists for that stack in humans.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tesofensine is a triple monoamine reuptake inhibitor (serotonin, dopamine, norepinephrine) that showed meaningful weight loss in a 2008 Phase 2 RCT but has not received FDA approval and carries documented cardiovascular side effects including elevated heart rate. The creator promotes it as both a cognitive enhancer and a GLP-1 adjunct for weight loss, neither of which has published clinical trial support. Patients on GLP-1 medications should not combine tesofensine without prescriber supervision, as no safety or efficacy data exists for that stack in humans.
- The Astrup et al. 2008 Lancet Phase 2 RCT showed roughly 10.6% body weight loss with tesofensine 0.5 mg over 24 weeks, which is a real and notable result.
- Tesofensine is not FDA-approved as of 2025 and is available in the US only through compounding pharmacies, meaning formulations are not standardized.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The Astrup et al. 2008 Lancet Phase 2 RCT showed roughly 10.6% body weight loss with tesofensine 0.5 mg over 24 weeks, which is a real and notable result.
- Tesofensine is not FDA-approved as of 2025 and is available in the US only through compounding pharmacies, meaning formulations are not standardized.
- No published clinical trial supports tesofensine as a treatment for brain fog or as a cognitive or energy enhancer.
- The Astrup 2008 trial documented elevated heart rate and dry mouth as common adverse effects, which the creator did not mention.
- There is no published human safety or efficacy data for combining tesofensine with semaglutide or tirzepatide.
- Triple monoamine reuptake inhibitors share a mechanism class with stimulant compounds, and cardiovascular screening before use is clinically appropriate.
- A social media call to action is not a clinical intake. Anyone considering tesofensine should speak with a licensed prescriber who can assess cardiac history and current medications.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Andrea Marie · TikTok creator
5.1K views on this video
🚀 Boost your weight loss journey with Tesofensine! 💪 Say goodbye to stubborn pounds and hello to confidence! ✨ Join the Tesofensine revolution and unleash your full potential! #WeightLossGoals #TesofensineMagic #ConfidenceBoost #Semaglutide #PeptidePower #Tirzepatide #telehealth #Weightlosspeptide #glp1forweightloss #glp1 #WeightLossJourney #VirtualHealth #virel
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Andrea Marie, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.